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ABSTRACT: The efficacy and tolerability of systemically administered anticancer agents are limited by their off-target effects. 
Precise spatiotemporal control over their cytotoxic activity would allow improving chemotherapy treatments, and light-regulated 
drugs are well suited to this purpose. We have developed phototrexate, the first photoswitchable inhibitor of the human dihydro-
folate reductase (DHFR), as a photochromic analog of methotrexate, a widely prescribed chemotherapeutic drug to treat cancer and 
psoriasis. Quantification of the light-regulated DHFR enzymatic activity, cell proliferation, and in vivo effects in zebrafish show 
that phototrexate behaves as a potent antifolate in its photoactivated cis configuration, and that it is nearly inactive in its dark-
relaxed trans form. Thus, phototrexate constitutes a proof-of-concept to design light-regulated cytotoxic small molecules, and a step 
forward to develop targeted anticancer photochemotherapies with localized efficacy and reduced adverse effects. 
INTRODUCTION 
Although the neoplastic process has been recognized for cen-
turies, the treatment and cure of cancer still represent one of 
the main challenges in medicine.1 Chemotherapy —the use of 
cytotoxic agents to kill the rapidly proliferating cells present in 
tumors— is one of the main actors in this fight, together with 
radiation therapy, hormone therapy and surgery.2 However, 
the efficacy, tolerability and acceptance of cancer chemother-
apy are in many cases dramatically limited by low therapeutic 
indices, non-specific targeting, and off-target toxicity of the 
drugs used, which is intrinsic to their antiproliferative effects.3 
Alternative strategies to overcome these drawbacks have 
emerged over the last years. 
One approach relies on the design of pharmacological agents 
interfering with targets that are overexpressed in tumor cells, 
i.e. growth factors, signaling molecules, cell-cycle proteins, 
and modulators of apoptosis and angiogenesis.1,4,5 However, 
despite remarkable achievements obtained recently, the devel-
opment of such targeted cancer therapies is hampered by the 
identification of tumor biomarkers, the selection of patient-
personalized treatments, and high costs.6,7 Another strategy to 
reduce off-target toxicity in cancer treatments relies on the de-
sign of engineered delivery systems (e.g., nanoparticles, lipo-
somes, micelles) that can selectively release the chemothera-
peutic at the tumor site. The increased availability of versatile 
materials and recent advances in the field of nanotechnology 
are certainly boosting this field, but yet the clinical translation 
of such drug carriers has been very limited so far.3 
A third approach to improve cancer therapies is to activate the 
drugs exclusively at their desired place of action.8 In fact, in 
cancer types and stages that would benefit from a highly local-
ized treatment, a precise spatiotemporal control over the activ-
ity of a cytotoxic agent would allow reducing the concentra-
tion of active compound outside the targeted neoplasm region, 
and would permit the administration of higher doses of drug. 
As a result, localizing drug activity would improve the effica-
cy of the treatment, reduce off-target effects, enhance the pa-
tients’ quality of life and therapeutic compliance. Light is a 
powerful tool in this respect.9,10 It offers unparalleled opportu-
nities as a non-invasive regulatory signal for biological and 
pharmacological applications because it can be delivered with 
high precision regarding space, time, intensity and wave-
length, it generally interacts weakly with tissue (except for 
scattering), and causes negligible toxicity for the human 
body.11,12,13,14,15 Several cancer treatments relying on the use of 
light have emerged during the last decades.8 One of those, 
known as photodynamic therapy (PDT), is already well estab-
lished and clinically applied. The procedure involves admin-
istration of a photosensitizer that forms reactive oxygen spe-
cies (ROS) upon irradiation with light at a specific wave-
length, leading to direct tumor cell death, damage to the mi-
crovasculature and induction of an inflammatory reaction.16 
Although PDT is on the rise as a cancer treatment modality, its 
dependence on the presence of molecular oxygen17,18,19 and the 
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frequent occurrence of unbearable inflammation-induced pain 
represent important drawbacks that can remarkably limit its 
applicability and success rate.20,21 Actually, oxygen-
independent treatments relying on the use of photoactivatable 
metal complexes22 or photoactivatable prodrugs (“caged com-
pounds”)23,24,25 have emerged as an alternative, but in these 
cases the irreversibility of activation of the cytotoxic species 
and their subsequent diffusion outside the intended site of ac-





Figure 1. Mechanism of action of methotrexate (MTX) and design strategy of phototrexate (PHX). (a) Chemical structure of the 
DHFR inhibitor MTX. (b) Mechanism of action of DHFR inhibitors (left) and cartoon representation of cell death (right) induced by a 
conventional versus a light-regulated DHFR inhibitor: the latter should be constitutively inactive and allow DHFR inhibition upon illumi-
nation at the proper wavelength. (c) Chemical structures of phototrexate in the trans (in the dark and under blue/white light illumination, 
structure in blue) and cis (under UVA illumination, structure in purple) configurations. The red dotted rectangle defines the moiety in-
volved in the azologization strategy. (d) Crystal structure of the human DHFR in complex with MTX (in orange) and the cofactor NADPH 
(in khaki) (PDB 1U72, protein surface representation with sectioning to reveal the active site pocket). The folded cis-like configuration 
adopted by MTX in the active site is shown. Docked structures of trans (in blue) and cis (in purple) phototrexate are also represented. 
(e),(f) Zoomed views of trans (in blue) and cis (in purple) phototrexate (best docked poses) superimposed on the crystallographic structure 
of MTX (in orange) in the active site of the human DHFR. In our docking simulations (see SI for details), unlike its trans counterpart, cis-
phototrexate shows a high degree of overlap to the crystallographic pose of MTX. Nitrogen and oxygen atoms of the ligands are colored in 





Overall, current strategies to improve the safety and efficacy 
of cancer treatment are promising, but the availability of truly 
tumor-selective therapies remains an unmet medical need. 
Photopharmacology, which relies on the use of reversibly pho-
toswitching drugs, is well-suited to this task.26,27,28,29 Several 
light-regulated compounds have been described to reversibly 
control a diversity of proteins. They are obtained by introduc-
tion of a molecular photoswitch into the structure of an exist-
ing drug in order to alter its pharmacological properties upon 
illumination.27 Azobenzenes, and more in general arylazo 
compounds, have been widely employed as molecular pho-
toswitches because of their favorable characteristics, namely 
design flexibility, ease of synthesis, large changes in geometry 
upon isomerization, relatively stable photostationary states and 
high quantum yields, fast photoisomerization rates, spontane-
ous relaxation to the thermodynamically more stable configu-
ration (T-type photoswitch), and low photobleaching rates.15 
Furthermore, the use of compounds bearing arylazo moieties 
has been proven safe in humans, including approved drugs and 
food colorants.27 Examples of bioactive molecules with pho-
toswitchable efficacy include G protein-coupled receptor 
modulators,30,31,32 ion channel modulators,33 enzyme inhibi-
tors,34 and inhibitors of protein-protein interactions.35 Recent-
ly, a number of photoswitchable cytotoxic agents acting on 
different biological targets have also been reported, thus 
demonstrating an increasing attention to this approach.9,36,37 
Indeed, photopharmacology has a transformative potential, by 
bringing together the advantages of targeted therapies and 
light-based oxygen-independent therapies in order to improve 
the safety and efficacy of anticancer treatments. Of relevance 
are the results obtained with photoswitchable combretastatin 
A-4 analogues, named photostatins or azo-combrestatins, act-
ing as tubulin polymerization inhibitors. Four research groups 
have independently published their findings on the efficacy of 
such derivatives as photoswitchable light-regulated cytotoxic 
agents in different cell lines.38,39,40,41 Another example was 
published by Szymanski and coll.10 Their photoswitchable his-
tone deacetylase inhibitor displayed a remarkable cytotoxicity 
in vitro and emerges as a putative lead compound for photo-
pharmacological chemotherapy.  
Here, we have taken one step further towards the development 
of light-regulated cancer chemotherapy by photocontrolling 
the in vitro antiproliferative action and in vivo toxicity of a 
target-specific, widely prescribed chemotherapeutic agent. For 
that purpose, we first performed a selection of protein targets 
and anticancer drugs complying with several criteria: (1) clini-
cally validated target, (2) wide application in high-incidence 
diseases, (3) in use to treat cancer forms affecting organs or 
tissues potentially accessible to light, either directly or through 
natural orifices (e.g., skin, bladder, intestine), (4) a drug safety 
profile including severe systemic side effects which currently 
limit its use, (5) drug structure suitable for photoregulation 
with minimal modifications, (6) biological inertness in the 
dark-relaxed form, (7) compatibility with phototherapy and/or 
used as adjunctive treatment, and (8) synthetic accessibility. 
We extensively documented the candidates using medical and 
scientific literature42,43 and public databases, including Drug-
Bank,44 ChEMBL,45 Protein Data Bank,46 and Drugs.com.47 
This survey ranked methotrexate (MTX) as one of the most 
prominent drugs matching the identikit to develop a light-
regulated cytotoxic agent (Figure 1a). 
MTX belongs to a specific class of chemotherapeutic agents 
known as antimetabolites, which kill hyperproliferative cells 
by targeting their metabolism. Although antimetabolites have 
been known for long, they are still actively developed for can-
cer chemotherapy and are widely used in the treatment of di-
verse human tumors.48,49 Notably, MTX inhibits dihydrofolate 
reductase (DHFR), which catalyzes the conversion of dihydro-
folate (dhf) to tetrahydrofolate (thf), a key step in folate me-
tabolism (Figure 1b). Interrupting folate metabolism compro-
mises thymidine synthesis, and interferes with purine synthesis 
and other reactions involving single-carbon transfers, leading 
to cell death (Figure 1b).48,50 MTX is commonly used alone or 
in combination with other antineoplastic drugs in the treatment 
of certain cancers including but not limited to breast cancer, 
epidermoid cancers of the head and neck, lung cancer (particu-
larly squamous cell and small cell types) and bladder cancer. 
In addition, because of its immunosuppressive properties, it is 
also indicated in the symptomatic control of severe, recalci-
trant, disabling psoriasis, and in the management of severe, 
active rheumatoid arthritis.51 However, the importance and 
ubiquity of the MTX target (DHFR) in all cell types is at the 
origin of a poor drug safety profile that often leads to unbeara-
ble side effects requiring dose reduction or treatment cessa-
tion. The most frequently reported adverse reactions include 
ulcerative stomatitis, leukopenia, nausea, abdominal distress, 
malaise, undue fatigue, chills and fever, dizziness, and de-
creased resistance to infection.52 
Besides the motivation to enhance the pharmaco-toxicological 
profile of MTX, two reasons supported the feasibility of pho-
tocontrolling MTX activity. The first one is that azobenzene 
analogs of the MTX structure can be readily designed. There 
are two general strategies to devise arylazo-based light-
regulated drugs: (1) by elongation of the drug structure with an 
arylazo moiety (“azo-extension”),53,54,55 and (2) by incorpora-
tion of an arylazo moiety into the pharmacophore of the drug 
(“azologization”).30,56 MTX is suitable for the latter, which is 
generally preferred because it requires minimal modifications 
of the original structure, thus maintaining the druglikeness of 
the parent compound, and largely preserving its pharmacoki-
netic and pharmacodynamic properties (Figure 1c).57 The se-
cond reason is that the activity of MTX azologs is expected to 
be higher in their cis state (“cis-on”) than in the most thermo-
dynamically stable trans configuration. This prediction is 
based on the crystal structure of the ternary complex of MTX 
with the wild-type human DHFR and the cofactor NADPH 
(PDB 1U72),58 in which MTX is bound to the enzyme active 
site in a bent “cis-like” configuration (Figure 1d-f). When de-
signing bioactive azologs, a “trans-off/cis-on” behavior is of-
ten desired because such compounds can be safely applied 
(e.g., systemically) in the inactive relaxed form and they can 
be photoactivated at the required times and locations. Thus, 
MTX azologs fulfill all the above-mentioned structural and 
(photo)pharmacological design requirements of a cis-on drug-
like antifolate candidate for light-regulated chemotherapy. 
 
RESULTS AND DISCUSSION 
Design strategy and synthesis. MTX structural azologs 
could be designed by replacing the methyleneamino bridge 
between the diaminopteridine and the benzamido moieties 
with an azo (–N=N–) group. However, before applying this 
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strategy, we reviewed the structure-activity relationships of 
MTX and related analogs in order to define the role of this 
bridge. We found out that a great variety of structural variants 
of the bridge are tolerated, and some of them can even favor 
the accumulation and persistence of the drug in responsive 
tumor cells rather than in normal proliferative tissues.59,60 
Moreover, it is reported that 5,8-dideaza (quinazoline) DHFR 
inhibitors obtained by isosteric replacement of the nitrogen 
atoms at positions N5 and N8 (–N=C) of the pteridine ring 
with –CH= groups are endowed with comparable inhibitory 
activity.61,62 In this regard, generating a diazo bond at position 
C6 of a quinazoline is expected to be more synthetically ac-
cessible than at a pteridine, while still providing a strong 
DHFR inhibitor. Thus, we conceived a putative photochromic 
DHFR inhibitor by MTX azologization and two bioisosteric 
substitutions, and named it phototrexate (PHX, Figure 1c). 
In order to achieve the desired biological properties (Figure 
1b), phototrexate should be constitutively inactive in its most 
thermodynamically stable configuration (trans isomer, dark-
adapted state), and it should mimic the pharmacological ef-
fects of the parent drug (MTX) upon illumination at the proper 
wavelength (cis isomer). To test the feasibility of our design, 
we performed molecular docking simulations of cis- and 
trans-phototrexate in the atomic structure of the human DHFR 
(PDB 1U72).58 The results (see also SI for details) show that 
cis-phototrexate binds to the active site of the target enzyme in 
a mode that strictly mimics the orientation and conformation 
adopted by MTX in its crystallographic pose, with a root mean 
square deviation (RMSD) of 0.5 Å between the best-scoring 
pose of cis-phototrexate and the crystallographic pose of 
MTX, and a predicted binding energy of −10.8 kcal/mol (Fig-
ure 1f). In contrast, trans-phototrexate displayed a set of bind-
ing poses that barely overlapped with MTX, with a RMSD of 
4.8 Å between its best docked pose and the crystallographic 
pose of MTX, and a predicted binding energy of −9.3 kcal/mol 
(Figure 1d-f). Overall, these computational results lend sup-
port to the assumption of a “cis-on” antifolate behavior of pho-
totrexate and encouraged pursuing the synthesis of the target 
compound. 
Phototrexate was prepared via a convergent 4-step synthetic 
route starting from commercially available compounds 
(Scheme 1). To generate the diazo bond of phototrexate, we 
planned to perform a coupling reaction between its quinazo-
line and benzamido building blocks. The required amine and 
nitroso intermediates were therefore prepared for this purpose. 
A catalytic hydrogenation of 6-nitroquinazoline-2,4-diamine 
afforded the desired quinazoline-2,4,6-triamine (1) in high 
yield (98%), while (S)-diethyl 2-(4-
nitrosobenzamido)pentanedioate (2) was obtained by oxida-
tion of the corresponding amine with Oxone® in a biphasic 
system of dichloromethane and water. These intermediates 
were then combined under Mills conditions (55% yield) to 
give (S,E)-diethyl 2-(4-((2,4-diaminoquinazolin-6-
yl)diazenyl)benzamido)pentanedioate (3), which was finally 
hydrolyzed in alkaline conditions to provide phototrexate in 
high yield (95%). Physicochemical characterization of each 
intermediates and the final compound is provided in the SI 
file. 
 
Scheme 1. The chemical synthesis of phototrexate. 
 
Photochemical characterization. An essential require-
ment for using phototrexate as a light-dependent DHFR inhibi-
tor is that it efficiently responds to light, which means that it 
can be quickly photo-isomerized between two different con-
figurations with a relatively high degree of photoconversion 
(trans/cis ratio). UV/Vis absorption studies showed a robust 
photochromic behavior in aqueous solution. Phototrexate can 
be effectively isomerized from trans to cis with UVA light 
(375 nm), and back-isomerized from cis to trans with blue 
(460 nm) or white light (Figure S2). This transition is reversi-
ble and can be repeated several times without any noticeable 
loss of absorption (Figure S3). We then quantified by 1H-
NMR analysis the ratio between the two isomers at the photo-
stationary state (PSS). The amount of the thermodynamically 
less stable cis isomer shifted from 0% (dark-adapted state) to 
76% upon illumination with 375 nm light for 30 minutes (4.6 
J/cm2, Figure 2a). In addition, as phototrexate is a T-type pho-
toswitch, we also studied its spontaneous thermal relaxation 
(from cis to trans) in dark conditions. The measured half-life 
was approximately 690 min at 25 °C and 236 min at 37 °C in 
aqueous solution (Figure 2b). Finally, we investigated the time 
dependence (Figure 2c) and the light fluence dependence 
(Figure 2d) of the photoisomerization (from trans to cis) under 
UVA (375 nm) illumination. These results show that maximal 
photoconversion is achieved with a fluence greater than 0.6 
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show that it can be efficiently and reversibly photoisomerized 
using UVA and white light, and that it has a stability of sever-
al hours in the dark at the normal human body temperature. 
 
 
Figure 2. Photochemical characterization of phototrexate (PHX). (a) Composition of the photostationary state achieved after illumina-
tion with 375 nm light for 30 min (4.61 J/cm2) determined by 1H NMR (5 mM in methanol-d4). (b) Thermal relaxation of phototrexate 
(from trans to cis) in the dark at 25 °C (50 µM) and 37 °C (100 µM), measured by absorbance at 350 nm. Half-lives were estimated using 
the one-phase decay function in GraphPad Prism 6 (nonlinear regression curve fitting). (c) Time dependence of photoisomerization of pho-
totrexate (from trans to cis) under 375 nm light measured by absorbance of a 200 µM solution at 350 nm. Data were fitted to the one-phase 
decay function in GraphPad Prism 6 (nonlinear regression curve fitting). (d) Light fluence dependence of photoisomerization of phototrex-
ate (from trans to cis) under 375 nm light measured by absorbance of a 200 µM solution at 350 nm. Data were fitted to the four-parameter 
dose-response curve in GraphPad Prism 6 (nonlinear regression curve fitting). 
 
In vitro photopharmacological characterization. After 
obtaining the target chemical compound with the desired pho-
tochromic properties, we characterized its biological activity 
using in vitro assays. For convenience, in the text we will refer 
to the all-trans form of phototrexate in the dark-adapted state 
as trans-phototrexate, and to the cis-enriched form (obtained 
at the PSS upon illumination at 375 nm) as cis-phototrexate. 
We first assessed the ability of the two photoisomers of photo-
trexate to inhibit the purified target enzyme. To this end, we 
quantified DHFR activity using a colorimetric assay (see SI 
for details) and observed significant differences between the 
two isomers at 10 nM and 100 nM, with 10 nM cis-
phototrexate inhibiting DHFR activity more strongly (70%) 
than the trans isomer at the same concentration (21%) (Figure 
3a). The stronger inhibition capacity exhibited by cis-
phototrexate thus matched with our molecular docking simula-
tions and fulfilled the design requirements of a cis-on antifo-
late (Figure 1). 
We next examined the cytotoxicity of phototrexate in cells us-
ing a MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay for cell viability. HeLa 
cervical cancer cells were incubated with trans- and cis-
phototrexate for 24 hours at 37 °C, and cell viability was sub-
sequently measured. Methotrexate was tested in the same con-
ditions as the positive control. Cells were also incubated in 
vehicle solution (negative control wells) and used for normali-
zation of cell viability. The cis isomer caused significantly 
lower viability to HeLa cells than the trans isomer (Figure 3b), 
in line with the results obtained in the enzyme inhibition as-
say. Notably, 1 µM cis-phototrexate reduced viability to 27%, 
whereas the trans isomer barely altered it (88%). At the max-
imum concentration tested (100 µM), only 23% of cells sur-
vived to cis-phototrexate, against 78% for trans-phototrexate. 
A remarkable difference in IC50 was estimated for the two 
isomers, with a value of about 6 nM for the cis and 34 µM for 
the trans compound. Interestingly, cis-phototrexate was as ef-
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fective as the reference drug methotrexate, which reduced cell 
viability to 40% at 1 µM and 33% at 100 µM. Overall, these 
results indicate that MTX and cis-phototrexate have a similar 
cytotoxicity profile in HeLa cancer cells, whereas trans-
phototrexate is nearly inactive at the same concentrations. 
Considering that cis-phototrexate has a relatively short half-
life of thermal relaxation in the test conditions (~236 minutes 
at 37 °C, for an incubation time of 24 hours), the difference 
observed between cis and trans in terms of cytotoxicity is re-
markable. The effect of cis-phototrexate can be realistically 
ascribed to the disruption of the folate pathway, since this pro-
cess plays an essential role in the synthesis of DNA and RNA, 
in the metabolism of amino acids, and ultimately in the pro-
cess of cell division. Nevertheless, a diversity of effects of the 
two photoisomers on other biochemical pathways beside the 
folate pathway (e.g., inhibition of thymidylate synthase and 
glycinamide ribonucleotide transformylase),63 dissimilarities 
in cellular uptake and polyglutamation,63 or differences in off-
target binding to intracellular structures,64 as reported for 
MTX, should not be ruled out and could account for the dif-
ferences in drug sensitivity between assays with purified target 





Figure 3. In vitro pharmacological characterization of phototrexate (PHX). (a) Inhibition of DHFR activity at 1 nM, 10 nM and 100 
nM of trans (black) and cis (violet) phototrexate. Data are means of at least three independent experiments in triplicate or quadruplicate ± 
SEM. Results were analyzed by two-way ANOVA with Bonferroni's multiple comparisons test for statistical significance (GraphPad Prism 
6; adjusted p-value (*) ≤ 0.05). (b) HeLa cell viability assay at different concentrations of MTX, cis-phototrexate and trans-phototrexate. 
The relatively low vertical span and Hill coefficient of the sigmoidal curves of MTX and cis-phototrexate might be ascribed to short expo-
sure time of the cells to the drugs,65 saturation of the carrier-mediated uptake, and partitioning of the inhibitors into an inaccessible form at 
the higher concentrations.66 Data are means of at least three independent experiments in triplicate or quadruplicate ± SEM. Results were 
analyzed by two-way ANOVA with Bonferroni's multiple comparisons test for statistical significance (GraphPad Prism 6; adjusted p-value 
(****) ≤ 0.0001 for trans-phototrexate versus cis-phototrexate). 
 
 
Disruption of folate metabolism in zebrafish larvae.	
In view of the efficacy and light-regulation of phototrexate 
antiproliferative properties in vitro, we evaluated the perfor-
mance of our compound in a small animal model. Since 
DHFR inhibitors disrupt folate metabolism, they have a high 
impact at early stages of animal development. Zebrafish (Dan-
io rerio) embryos have been used to characterize the effects of 
methotrexate67 and thus constitute an excellent model system 
to investigate the effects of trans- and cis-phototrexate in vivo. 
Zebrafish fertilized eggs were incubated within 5 hours post 
fertilization (hpf) in UV purified water containing trans- or 
cis-phototrexate (200 µM) for 5 days at 28 °C. MTX was also 
tested as the positive control (200 µM). Each embryo (normal-
ly until 48-72 hpf) and hatched larva (from 48-72 hpf) was ob-
served daily to monitor changes in their anatomy and behav-
ior. The four groups (vehicle, MTX, cis-phototrexate, trans-
phototrexate) were compared at 72 and 96 hpf, when certain 
anatomical and behavioral traits become easier to observe 
(Figure 4a-d). In particular, healthy hatched larvae reach the 
stage of protruding-mouth at 72 hpf,68 with a length of about 
3.5 mm. Normal anatomical traits include iridiophores in the 
yolk and half of the eye, with yellow pigmentation on the head 
and in the dorsal part and black pigmented lateral and ventral 
stripes from the head to the tail, as well as observable heart 




Figure 4. Effects of phototrexate (PHX) on zebrafish development, viability and mortality. Experiment 1, panels a-d: cis-phototrexate 
was obtained by external pre-illumination with 375 nm light (see SI for details). (a), (c) Anatomical profiles of zebrafish at 72 hpf after 
treatment with vehicle (DMSO 2%), MTX (200 µM), cis-phototrexate (200 µM), and trans-phototrexate (200 µM). The graph shows the 
percentage of zebrafish treated versus the treatment group, superimposing the number of abnormal larvae (black and yellow checkered sec-
tions) to the number of viable embryos (checkered sections) and to the total number of fertilized embryos (whole columns). (b) Illustrative 
pictures of individual larvae from each treatment group at 72 hpf, showing the observable aberrant developmental traits in the MTX and 
cis-phototrexate groups. (d) Mortality of zebrafish at 96 hpf after treatment with vehicle (DMSO 2%), MTX (200 µM), cis-phototrexate 
(200 µM), and trans-phototrexate (200 µM). The graph shows the percentage of zebrafish treated versus the treatment group, superimpos-
ing the number of dead zebrafish (black and red checkered sections) to the number of viable embryos (checkered sections) and to the total 
number of fertilized embryos (whole columns). Experiment 2, panels e-f: cis-phototrexate was obtained by in situ illumination with 375 
nm light in the presence of zebrafish. (e) Anatomical profiles of zebrafish at 96 hpf after treatment with vehicle/dark (DMSO 2%, no illu-
mination), vehicle/375 nm light (DMSO 2%, 0.61 J/cm2, 4 min illumination twice a day), trans-phototrexate (200 µM, dark), and cis-
phototrexate (200 µM, 0.61 J/cm2, 4 min illumination twice a day). The graph shows the percentage of zebrafish treated versus the treat-
ment group, superimposing the number of abnormal larvae (black and yellow checkered sections) to the number of viable embryos (check-
ered sections) and to the total number of fertilized embryos (whole columns). (f) Mortality of zebrafish at 96 hpf after treatment with vehi-
cle/dark (DMSO 2%, no illumination), vehicle/375 nm light (DMSO 2%, 0.61 J/cm2, 4 min illumination twice a day), trans-phototrexate 
(200 µM, dark), and cis-phototrexate (200 µM, 0.61 J/cm2, 4 min illumination twice a day). The graph shows the percentage of zebrafish 
treated versus the treatment group, superimposing the number of dead zebrafish (black and red checkered sections) to the number of viable 
embryos (checkered sections) and to the total number of fertilized embryos (whole columns). 
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Embryos treated with MTX presented a low viability at 24 
hpf, with six out of seventeen total embryos viable (35%, Fig-
ure 4a). At 72 hpf, all six individuals presented three abnor-
malities: a deficient iridiophore ocular pigmentation, with 
complete black colored eyes and a deficient black body stripe 
patterns; an abnormal volume of the cardiac cavity; and tail 
angle deviations, with prominent bent or curved tails (Figure 
4b). Viability in the vehicle and cis-phototrexate groups re-
mained within normal batch levels (only two and one non-
viable embryos, respectively), and perfect in the trans-
phototrexate group (Figure 4b-c). In the vehicle group, only 
one larva presented malformation, a non-hatched individual 
with unformed tail. Cis-phototrexate produced a toxicity pro-
file similar to that of the reference compound MTX, generat-
ing comparable developmental abnormalities at 72 hpf togeth-
er with a high rate of mortality at 96 hpf (Figure 4d). In stark 
contrast, trans-phototrexate showed a lower general toxicity, 
as it did not produce any observable abnormality at 72 hpf and 
no mortality at 96 hpf. 
Next, we tested the performance of phototrexate by pho-
toswitching its pharmacological effects in situ. We used again 
zebrafish as animal model. Four groups of zebrafish fertilized 
eggs (n = 48 in each group) were incubated within 5 hours 
post fertilization (hpf) in UV purified water containing the 
drug vehicle (DMSO 2%, groups 1 and 2) or phototrexate (200 
µM, groups 3 and 4) for 5 days at 28 °C (Figure 4e-f). Groups 
1 and 3 (vehicle and trans-phototrexate) were constantly kept 
in the dark, whereas group 4 was illuminated twice a day with 
375 nm light (0.61 J/cm2, 4 min illumination) to generate a 
significant amount of cis-phototrexate directly in the fish me-
dium. Group 2 (vehicle) underwent a parallel and identical 
protocol of illumination to determine whether the direct expo-
sure to UVA light could intrinsically affect fish development 
and survival. The viability of individual embryos and hatched 
larvae was monitored daily. The four groups were finally ex-
amined at 96 hpf to assess the abnormality and mortality pro-
files (Figure 4e-f). All groups presented normal development 
and a good viability at 24 hpf (greater than 80%). When com-
paring the number of larvae with anatomical malformations 
and abnormalities to the total number of embryos, both vehicle 
groups (dark and UVA) presented 12% of abnormal individu-
als (with anomalous volume of the cardiac cavity and sidewise 
position) at 96 hpf. In the trans-phototrexate group, 30% of 
the larvae were affected by abnormalities, including cardiac 
cavity and curved tails, while 60% of the individuals were 
found with a similar profile of abnormalities and lower pig-
mentation in the group where phototrexate was switched on 
(cis isomer) with UVA light (Figure 4e). Analyzing the mor-
tality profile at 96 hpf, the vehicle/dark group did not show 
any loss of individuals, and only 2% were found dead in the 
vehicle/UVA group. Therefore, the light intensity, light wave-
length and illumination protocol adopted for the experiment 
were well tolerated by the fish. Importantly, we found out that 
only 6% of the total embryos (7% of the viable ones) were 
dead in the trans-phototrexate group against the 46% of the 
total embryos (51% of the viable ones) in the cis-phototrexate 
group (Figure 4f). Thus, the abnormality and mortality rate in 
the fish wells in which phototrexate was switched on with 
light was remarkably higher than those maintained in the dark 
(two- and eight-fold, respectively). These results (Figure 4e-f) 
are in good agreement with those obtained in the previous ex-
periment (Figure 4a-d) and demonstrate that the cytotoxic ef-
fects of phototrexate can be turned on also by direct illumina-
tion of living animals treated with its trans “inactive” form. 
Overall, our experiments in vivo, together with the in vitro as-
says (Figure 3), indicate that photoactivated cis-phototrexate 
has a pharmacological profile of a potent antifolate drug, 
whereas it is almost inert in its trans configuration. Slight dis-
crepancies observed between MTX and cis-phototrexate activ-
ities on cellular and organism assays might be related in part 
to non-identical off-target activities. 
 
CONCLUSIONS 
In summary, we have rationally designed, synthesized, and 
characterized phototrexate, the first light-regulated inhibitor of 
the human DHFR, and we have demonstrated its antifolate and 
antiproliferative properties using in vitro and in vivo assays. 
Phototrexate has been derived by azologization and bioisoster-
ic substitutions of methotrexate, a DHFR inhibitor that is ex-
tensively used to treat many forms of cancer, severe psoriasis 
and rheumatoid arthritis. In this way, the activity, drug-
likeness and other determinants of the pharmacokinetic profile 
of the parent compound should be retained. Our results show 
that phototrexate can be switched on with UVA light to be-
come a potent antifolate drug comparable to methotrexate, and 
it can be switched off with blue or white light and by thermal 
relaxation in the dark. This profile offers the opportunity of 
inhibiting cellular proliferation in a target-specific manner and 
at confined locations, while reducing these effects in other re-
gions. In addition, light-activated phototrexate self-deactivates 
(thermally relaxes) upon diffusing away from the treated re-
gion. Thus, phototrexate constitutes a proof-of-concept to de-
velop photoswitchable antimetabolite drugs, and makes it pos-
sible to explore photopharmacological chemotherapies with 
reduced systemic side effects and with enhanced tolerability 
and antineoplastic efficacy. Major advantages of such light-
based approach over the existing ones are that the effects of 
photoswitchable chemotherapeutics like phototrexate are tar-
get specific (cf. PDT), oxygen-independent (cf. PDT), and re-
versible (cf. PDT, photoactivatable metal complexes, and pho-
tocleavable prodrugs). Small molecules like phototrexate 
could be administered topically in their active form, or system-
ically in their inactive form followed by precise photoactiva-
tion only at the lesion area. Target regions might be tissues 
that can be exposed to illumination, like the skin and the di-
gestive, respiratory and reproductive tracts. Notably, the en-
visaged therapy may also benefit of medical devices and tech-
nologies currently in use for clinically approved light-based 
therapies (e.g., PDT, PUVA), thus facilitating its medical and 
regulatory acceptance. Furthermore, phototrexate could also 
be used as a powerful tool to study developmental processes 
with high spatiotemporal precision. The wavelength needed to 
switch phototrexate on can be scattered and absorbed by hu-
man tissue, and displays low skin penetration (below 0.3 
mm).69 However, new derivatives can be developed that pho-
toisomerize at wavelengths where penetration though body 
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